Señales en vivo de XNCR | Maximiza tus Ganancias con Getagraph.com

VENDER 107089 min ago

@ $19.46

Emitido: 14 feb 2024 @ 09:30

Retorno: 2.67%

Señal anterior: feb 13 - 09:31

Señal anterior: Comprar

Retorno: -3.52 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	355 716
Volumen promedio	692 466
Capitalización de mercado	1.23B
EPS	$0 ( 2024-02-27 )
Próxima fecha de ganancias	( $-0.0900 ) 2024-05-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.61
ATR14	$0.0250 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Cornelissen Bart Jan	Buy	190 194	Stock Option (Right to Buy)
2024-04-09	Cornelissen Bart Jan	Buy	42 265	Common Stock
2024-04-09	Cornelissen Bart Jan	Buy	0
2024-03-11	Kuch John J	Sell	849	Common Stock
2024-03-11	Eckert Celia	Sell	850	Common Stock

INSIDER POWER
65.95
Last 96 transactions
Buy: 2 831 480 \| Sell: 458 022

Volumen Correlación

Largo: -0.17 (neutral)

Corto: -0.79 (moderate negative)

Signal:(19.267) Neutral

Xencor Inc Correlación

10 Correlaciones Más Positivas
THRX	0.898
WDC	0.891
PALT	0.886
TREE	0.883
OZKAP	0.882
OTRK	0.881
XPEL	0.873
HLMN	0.871
MBIO	0.869
TCBIO	0.862

10 Correlaciones Más Negativas
GLDI	-0.814
CFV	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xencor Inc Correlación - Moneda/Commodity

0.23
( neutral )

0.16
( neutral )

0.00
( neutral )

0.32
( neutral )

0.10
( neutral )

-0.40
( neutral )

Xencor Inc Finanzas

Annual	2023
Ingresos:	$168.34M
Beneficio Bruto:	$156.84M (93.17 %)
EPS:	$-2.08

FY	2023
Ingresos:	$168.34M
Beneficio Bruto:	$156.84M (93.17 %)
EPS:	$-2.08

FY	2022
Ingresos:	$164.58M
Beneficio Bruto:	$155.78M (94.65 %)
EPS:	$-0.930

FY	2021
Ingresos:	$275.11M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$1.440

Financial Reports:

No articles found.

Xencor Inc

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.